Log in to search using one of your social media accounts:

 

Medical News Today: Six yoga poses for prostate enlargement
Yoga has many benefits, In this article, learn about six yoga poses that can help ease and manage the symptoms of benign prostatic hyperplasia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2017 Category: Consumer Health News Tags: Men's Health Source Type: news

Merit Medical licenses KatGuide pleural drain tech from Pleuratech
Merit Medical (NSDQ:MMSI) has licensed a novel surgical device designed to ensure drain placement in the pleural cavity from Pleuratech, according to a Young America Capital press release posted this week. The device is Denmark-based Pleuratech’s flagship product, the KatGuide, and is designed to guide chest tubes to the part of the pleural cavity which needs draining to reduce misplaced drains and increase surgical success rates. The companies did not release the exact terms of the deal, but said that it was a multimillion dollar license agreement, according to a press release. “As a leading manufacturer ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Surgical Merit Medical Systems Inc. pleuratech Source Type: news

Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH
Photoselective vaporization of the prostate (PVP) offers similar efficacy with better quality of life, compared with transurethral resection of the prostate (TURP), in men with benign prostatic hyperplasia (BPH), researchers from Italy report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

How Teleflex Bagged a $1.1 Billion Hidden Treasure
Teleflex CEO Benson Smith expected some investors to be surprised by yet another billion-dollar acquisition, but sometimes businesses simply must strike while the iron is hot. The Wayne, PA-based company said it will buy NeoTract for up to $1.1 billion. The deal comes just seven months after Teleflex completed its $1 billion acquisition of Vascular Solutions. "I'm sure that at least some of you may be a bit surprised that Teleflex is once again active in M&A so quickly after announcing the acquisition of Vascular Solutions. Well, we are not," Smith said Tuesday during a conference call. Smith said Teleflex ha...
Source: MDDI - September 5, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Teleflex to pay $1.1B for NeoTract
Teleflex (NYSE:TFX) said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment. The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughl...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat NeoTract Teleflex Source Type: news

NxThera adds $6m for Rez ūm prostate device
NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13. NxThera said it’s looking to raise an additional $5.8 million in the round, taking the total hoped-for raise from $15 million to $26.4 million. In Dec. 2015, Boston Scientific (NYSE:BSX) led a $40 million funding round for NxThera and its Rezūm device, saying it plans to boost its sales footprint in the U.S. an...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Urology Wall Street Beat NxThera Inc. Source Type: news

7 medtech stories we missed this week: July 7, 2017
[Image from unsplash.com]From EnvisionTEC’s FDA approval to InVivo Therapeutics adding a new clinical site, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EnvisionTEC wins FDA nod for 3D printing E-Denture material EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material for 3D printing dentures. The company already has the E-Dent 100 and 400 materials approved for the printing of restorations that simulate teeth. The new approval makes EnvisionTEC the only 3D printing company worldwide that has a complete digital den...
Source: Mass Device - July 7, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Dental Food & Drug Administration (FDA) Imaging Implants Research & Development Adin Dental Implant Systems EnvisionTEC InVivo Therapeutics Life Spine Inc. MedTech NeoTract SpineGuard SpineWave Telerad Tech Ze Source Type: news

Tamsulosin and Naftopidil Offer Similar Benefits in BPH Tamsulosin and Naftopidil Offer Similar Benefits in BPH
Bladder storage symptoms associated with benign prostatic hyperplasia (BPH) improve to a similar extent with tamsulosin and naftopidil treatment, researchers from South Korea report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA grants de novo clearance for Merit Medical ’ s Embosphere
Merit Medical (NSDQ:MMSI) said yesterday that its Embosphere device won expanded de novo clearance from the  to treat benign prostatic hyperplasia. The federal safety watchdog’s clearance means Embosphere can be used in prostatic artery embolization  procedures to treat BPH. “Merit’s Embosphere is the first embolic agent to receive FDA 513(f)(2) classification for prostatic artery embolization, providing a non-surgical treatment option for millions of men who suffer from BPH,” chairman & CEO Fred Lampropoulos said in prepared remarks. The device is designed to occlude th...
Source: Mass Device - June 23, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Urology Merit Medical Systems Inc. Source Type: news

Popular prostate drug linked to serious side effects
(Boston University Medical Center) Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2017 Category: International Medicine & Public Health Source Type: news

2017 Eureka! Innovation award winner: NxThera Inc.
Industry category: Health Care Technology Organization size: Small — revenue less than $50 million Eureka! idea: Uses water vapor to treat endourological diseases that affect millions of men, with a safe, effective and fast procedure What the judges said:"The team is great. It's a slick treatment option — killing cells in the gentle st way possible." Benign prostatic hyperplasia, an enlargement of the prostate gland, affects 12 million men in the United States, with nearly 800,000 new diagnoses… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2017 Category: Biotechnology Source Type: news

2017 Eureka! Innovation award winner: NxThera Inc.
Industry category: Health Care Technology Organization size: Small — revenue less than $50 million Eureka! idea: Uses water vapor to treat endourological diseases that affect millions of men, with a safe, effective and fast procedure What the judges said:"The team is great. It's a slick treatment option — killing cells in the gentle st way possible." Benign prostatic hyperplasia, an enlargement of the prostate gland, affects 12 million men in the United States, with nearly 800,000 new diagnoses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 21, 2017 Category: American Health Source Type: news

7 medtech stories we missed this week: May 26, 2017
[Image from unsplash.com]From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The licensing agreement is going to help with the development, manufacture and commercialization of an investigation preclinical antibody candidate that targets the protein tau. Merck will have exclusive worldwide rights to develop, manufa...
Source: Mass Device - May 26, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Patient Monitoring Pharma Pharmaceuticals Research & Development Surgical EarlySense Janssen Pharmaceuticals Life Spine Inc. Masimo MedTech Merck Midmark Procept BioRobotics Shenzhen Lachesis Mhealth Teijin Pharma Thermi Source Type: news

7 medtech stories we missed this week: May 19, 2017
[Image from unsplash.com]From FDA clearances to touting study data, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. XpandOrtho wins FDA 510(k) clearance XpandOrtho announced in a May 17 press release that it has received FDA 510(k) clearance for its electronic soft tissue balancing instrument for total knee replacement surgery. The sterile-packaged wireless disposable device uses miniature sensors and actuators to balance knee joints during full-range motions. Using constant pressure bellows systems, the device communicates with a display for multiaxial balance and selection of th...
Source: Mass Device - May 19, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Body Vision Medical Exactech Inc. Lombard Medical Technologies MedTech NxThera Inc. Rivanna Medical Visionsense XpandOrtho Source Type: news

Enlarged Prostate ( BPH, Benign Prostatic Hyperplasia)
Title: Enlarged Prostate ( BPH, Benign Prostatic Hyperplasia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/18/2017 12:00:00 AM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - May 18, 2017 Category: Primary Care Source Type: news

Enlarged Prostate (BPH, Benign Prostatic Hyperplasia)
Title: Enlarged Prostate (BPH, Benign Prostatic Hyperplasia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/18/2017 12:00:00 AM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - May 18, 2017 Category: Primary Care Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. 10 innovative diagnostic tests to combat diseases Medtech is seeing new exciting developments in the field of medical diagnostics, with recent innovations allowing for faster disease diagnosis than ever before. We cover 10 diag...
Source: Mass Device - May 17, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

NeoTract touts 5-year UroLift study data
NeoTract  today presented 5-year results from the pivotal Lift IDE study of its UroLift system, touting rapid reduction of symptoms and sustained effects in treating patients with symptomatic benign prostatic hyperplasia. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. The 5-year results were presented by Dr. Claus Roehrborn of Dallas’ UT Southwestern Medical Center at the 112th annual American Urological Association meeting...
Source: Mass Device - May 16, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Urology NeoTract Source Type: news

7 medtech stories we missed this week: May 12, 2017
[Image from unsplash.com]From Bioness’s new distribution deal to InBrace’s launch of new braces technology, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Obalon receives approval to commercialize in Middle East Obalon Therapeutics announced in a May 11 press release that it has received regulatory approvals in select Middle East markets to commercialize its 6-month, gas-filled intragastric balloon system. The FDA-approved, swallowable balloon system is designed to treat obesity and is the first and only system of its kind. The regulatory approval also accounts for it...
Source: Mass Device - May 12, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News Patient Monitoring Regulatory/Compliance Research & Development Surgical Bioness Inc. InBrace LensAR Inc. MedTech Obalon Therapeutics Ottobock SRS Medical Teleon Surgical ZipLine Medical Source Type: news

7 medtech stories we missed this week: March 31, 2017
[Image from unsplash.com]This week we saw a few FDA 510(k) clearances and one of the 1st uses of a next-generation surgical robot in Asia. Here are 7 medtech stories we missed this week but thought were still worth mentioning: 1. Corindus touts first Asian use of next-generation robot Corindus Vascular Robotics announced in a March 31 press release that robot-assisted PCI procedures were performed for the first time in Asia using the CorPath GRX system. The procedures were performed at Fu Wai Hospital. This is the first time the system has been used outside of the U.S. CorPath GRX enhances the precision and workflow of the...
Source: Mass Device - March 31, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Clinical Trials Food & Drug Administration (FDA) Robot-Assisted Surgery Robotics Stent Grafts Amniox Bodycad Corindus Endologix MedTech NeoSurgical NeoTract Providence Medical Tissuetech Source Type: news

Revolutionary UroLift(R) System Launches in Ireland
Innovative UroLift System to Treat Enlarged Prostate ready for roll out to Irish patients nationally PLEASANTON, California, March 23, 2017 -- (Healthcare Sales & Marketing Network) -- NeoTract, Inc., announced today that the largest private health ins... Devices, Urology, Product Launch NeoTract, UroLift, Benign Prostatic Hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

NxThera raises $15 million
NxThera  has raised $14.6 million in a new round of debt financing, according to an SEC filing posted this week. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the 1st sale noted on Jan. 13. NxThera is looking to raise an additional $809,831 in the round, and noted on the SEC filing that the amount sold does not include foreign purchasers. The company has not yet stated how it plans to spend funds raised in the round. In Dec. 2015, NxThera said that Boston Scientific (NYSE:BSX) led a $40 mill...
Source: Mass Device - March 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News NxThera Inc. Source Type: news

What Every Man Must Know About BPH
One of the most common conditions a man can get affecting his prostate is benign prostatic hyperplasia or BPH. BPH is an enlargement of the prostate putting pressure on the urethra making it difficult to urinate along with other symptoms associated with it. It becomes more prevalent as a man ages with the risk of BPH increasing each year after a man turns 40. By age 60, more than half of all men will have BPH and by age 85, about 90 percent of men have this condition. How will a man know if he has BPH? Most of the signs and symptoms of BPH are urinary related. The prostate gland, the size of a walnut, surrounds the urethra...
Source: Healthy Living - The Huffington Post - February 28, 2017 Category: Consumer Health News Source Type: news

NxThera raises $12.2m
NxThera raised $12.2 million in a new round of financing, according to an SEC filing posted this week. Funds in the round come through the offering of debt, warrants, convertible promissory notes and Series C preferred stock warrants, according to the filing. Funds in the round were raised by 28 unnamed US purchasers, according to the SEC filing, and the company has not yet stated how it plans to use funds raised. Last December, NxThera said that Boston Scientific (NYSE:BSX) led a $40 million funding round for its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe. Existi...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News NxThera Inc. Source Type: news

Guidelines for the Treatment of Benign Prostatic Hyperplasia Guidelines for the Treatment of Benign Prostatic Hyperplasia
This article presents an overview of the many therapeutic options for benign prostatic hyperplasia, including lifestyle modifications, pharmacotherapy, and surgical interventions.U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 3, 2017 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Dr. David Samadi Explains Why Enlargement Of The Prostate Is More...
Dr. David Samadi gives his opinion on a recent retrospective cohort study out of Korea on findings showing benign prostatic hyperplasia is more likely to develop in men having a high body mass index...(PRWeb January 24, 2017)Read the full story at http://www.prweb.com/releases/David_Samadi/BPH/prweb14004896.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 24, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Benign Prostatic Hyperplasia: Treatment, Symptoms, and Causes
What is BPH and what are the causes and risk factors? Learn about its diagnosis, complications, medication that may be used, and tips for living with BPH. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 4, 2017 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

unctional Autoantibodies May Promote BPH unctional Autoantibodies May Promote BPH
Overstimulation by autoantibodies targeting the endothelin A receptor (ETA-AABs) may play a role in the development of benign prostatic hyperplasia (BPH), new research suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 16, 2016 Category: Pathology Tags: Urology News Source Type: news

Functional Autoantibodies May Promote BPH Functional Autoantibodies May Promote BPH
Overstimulation by autoantibodies targeting the endothelin A receptor (ETA-AABs) may play a role in the development of benign prostatic hyperplasia (BPH), new research suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 16, 2016 Category: Pathology Tags: Urology News Source Type: news

Prostatic Urethral Lift Relieves BPH Symptoms Prostatic Urethral Lift Relieves BPH Symptoms
The prosthetic urethral lift (PUL) procedure relieves lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), researchers report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 29, 2016 Category: Surgery Tags: Urology News Source Type: news

Neotract touts coverage win for UroLift prostate device
NeoTract said today it won coverage for its Urolift system from Medicare Administrative Contractor First Coast Service Options. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. First Coast Service Options covers Florida, Puerto Rico and the U.S. Virgin Islands, the Pleasanton, Calif.-based company said. “We are thrilled that millions of men across the United States now have access to the UroLift System treatment. The recently publ...
Source: Mass Device - November 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology NeoTract Source Type: news

Benign Prostatic Hyperplasia (BPH) Treatment Should Be Individualized...
BPH affects approximately 50% of men between the ages of 51 - 60 & up to 90% of men over the age of 80. Men need to work with their doctor to determine which treatment option is right for them.(PRWeb October 04, 2016)Read the full story at http://www.prweb.com/releases/BPH_Enlarged_Prostate/David_Samadi/prweb13732813.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 4, 2016 Category: Pharmaceuticals Source Type: news

NeoTract touts reimbursement win for UroLift
NeoTract today touted a reimbursement win from Geisinger Health Plan and EmblemHealth that will allow coverage for procedures using its UroLift system for patients with benign prostatic hyperplasia. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. Geisinger Health Plan serves 540,000 members in Pennsylvania, New Jersey, Delaware, Main and West Virginia, while EmblemHealth serves New York, New Jersey and Connecticut. “We are please...
Source: Mass Device - October 3, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology NeoTract Source Type: news

BPH Drugs Don't Independently Raise the Risk of ED: Study BPH Drugs Don't Independently Raise the Risk of ED: Study
A large observational study finds no evidence that use of 5-alpha-reductase inhibitors for benign prostatic hyperplasia (BPH) or alopecia raise the risk of erectile dysfunction.Reuters Health Information (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 29, 2016 Category: Urology & Nephrology Tags: Urology News Source Type: news

National Prostate Cancer Awareness Month -- Educating All Men On Reducing Their Risk
This study only looked at the effect of dietary or food sources of zinc and not at zinc supplements. Some dietary sources of zinc include the following: • Beef steak - 3 oz contains 4.9 mg • Oysters - 3 oz contains 67 mg • Shrimp - 3 oz contains 1.5 mg • Pork chop - 3 oz contains 2.8 mg • Yogurt - 1 cup contains 2.2 mg • Enriched cereal - ¾ cup contains 15 mg • Red kidney beans - ½ cup contains 2 mg Zinc coming from meat sources is more readily bioavailable than zinc from vegetarian sources. Legumes and whole grains contain phytic acid inhibiting zinc's bioavailability. Co...
Source: Healthy Living - The Huffington Post - September 23, 2016 Category: Consumer Health News Source Type: news

Finasteride, Dutasteride Don't Seem to Increase Risk for Erectile Dysfunction (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS The 5-alpha reductase inhibitors finasteride and dutasteride do not appear to increase risk for erectile dysfunction in men with benign prostatic hyperplasia … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 22, 2016 Category: Primary Care Source Type: news

Ultrasound Noninvasively Detects Bladder Outlet Obstruction Ultrasound Noninvasively Detects Bladder Outlet Obstruction
Bladder and prostate ultrasonography noninvasively detects bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia (BPH), researchers from Saudi Arabia report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 21, 2016 Category: Radiology Tags: Urology News Source Type: news

Audax deals Laborie Medical to Patricia Industries
Private equity player Audax Group said today it sold Laborie Medical Technologies to Investor AB subsidiary Patricia Industries for an undisclosed amount. Toronto-based Laborie Medical Tech develops and manufactures urological, pelvic health and gastrointestinal medical devices used for diagnosis and treatment of urinary incontinence and other urological and GI conditions, Audax Medical said. Laborie acquired the pelvic muscle rehabilitation business of UroMed Technology in October 2013 for an undisclosed amount. “Under Audax’ ownership, Laborie transformed from a manufacturer of capital equipmen...
Source: Mass Device - September 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Mergers & Acquisitions Urology Wall Street Beat Audax Group Laborie Medical Technologies Source Type: news

Enlarged prostate: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, we hear from Dr. Amy Krambeck about enlarged prostates, a condition know as benign prostatic hyperplasia.. To listen, click the link below. Enlarged Prostate (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 15, 2016 Category: Databases & Libraries Source Type: news

Medical News Today: Enlarged prostate: Molecular mechanism clue may explain link to inflammation
Discovery of molecular mechanism may explain how inflammation leads to benign prostatic hyperplasia and improve response to androgen-targeted therapies. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2016 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Serendipitous finding leads scientists to propose mechanism to explain benign prostatic hyperplasia
Benign prostatic hyperplasia affects about half of men between 51 and 60 years of age, and nine out of 10 men older than 80. How BPH happens, however, is still open for debate. A new report outlines a new mechanism that can explain the development of BPH and suggest strategies to improve the response to androgen-targeting therapies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 1, 2016 Category: Science Source Type: news

Serendipitous finding leads scientists to propose mechanism to explain benign prostatic hyperplasia
(Baylor College of Medicine) Benign prostatic hyperplasia affects about half the men between 51 and 60 years of age, and nine out of 10 men older than 80. How BPH happens, however, is still open for debate. In a paper published today in Molecular Cell, researchers at Baylor College of Medicine and other institutions report a new mechanism that can explain the development of BPH and suggest strategies to improve the response to androgen-targeting therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 1, 2016 Category: Cancer & Oncology Source Type: news

Button TURP vs. Green Light Laser for Benign Prostatic Hyperplasia -...
Button TURP and Green Light Laser are less invasive prostate surgeries used to treat BPH, a condition that affects 50% of men in their 50s and as many as 90% by the time a man reaches his 70s, or...(PRWeb August 10, 2016)Read the full story at http://www.prweb.com/releases/Dr_David_Samadi/BPH/prweb13605293.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2016 Category: Pharmaceuticals Source Type: news

Many Commonly Used Drugs Are Useless
Some medications are life saving. I am so thankful for the trusty med that tames my atrial fibrillation. Many meds are helpful -- demonstrating superiority to placebo in ways that are clearly clinically significant and life enhancing. But many (perhaps most) drugs are probably no more than very expensive placebos. Patients get prescriptions from doctors when their symptoms are most severe and improve with time and positive expectation, not because the med is really effective. Doctors and patients need independent, objective information on drug efficacy and risks. The multibillion dollar pharma marketing machine can tu...
Source: Science - The Huffington Post - August 7, 2016 Category: Science Source Type: news

Medi-Tate wins strategic investment from Canada’s Laborie Medical Technologies
Laborie Medical Technologies said it took out a stake in Israel’s Medi-Tate, which is developing devices to treat enlarged prostates, for an unspecified amount. Toronto-based Laborie, which is owned by private equity company Audax Group, in October 2013 acquired the pelvic muscle rehabilitation business of UroMed Technology, also for an undisclosed amount. Akiva, Israel-based Medi-Tate developed a minimally invasive treatment for benign prostate hyperplasia called iTind, which uses a 5-day implant to reshape the urethra and create new channels for urine flow. It’s designed to ...
Source: Mass Device - July 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Urology Wall Street Beat Laborie Medical Technologies Medi-tate Ltd. Source Type: news

NeoTract logs reimbursement wins for UroLift prostate treatment
NeoTract said today that it logged several reimbursement wins for its UroLift treatment for enlarged prostates, including a Medicare contractor and at least 7 independent insurers. The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. Today NeoTract said Medicare contractor National Government Services agreed to cover UroLift patients in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, ...
Source: Mass Device - July 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Urology Blue Cross Blue Shield Centers for Medicare and Medicaid Services (CMS) Kaiser Permanente NeoTract Reimbursement SelectHealth Source Type: news

UroLift Device Useful, But Likely Not a Game-Changer for Treating BPHUroLift Device Useful, But Likely Not a Game-Changer for Treating BPH
Placement of the UroLift device provides durable relief of benign prostatic hyperplasia (BPH) symptoms at 12 months and leads to improvements in both subjective and objective outcome measures, according to a recent systematic review of research on this treatment. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2016 Category: Consumer Health News Tags: Urology News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 16, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Si-Bone touts updated 510(k) clearance indications, MAC reimbursement wins for iFuse Si-Bone said this week it won updated 510(k) clearance indications for its iFuse implant system and reimbursement coverage for its minimally in...
Source: Mass Device - June 16, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Benign Prostatic Hyperplasia and Complementary and Integrative Approaches
Research results on complementary and integrative health approaches benign prostatic hyperplasia, including acupuncture, lycopene, Pygeum africanum, saw palmetto, and urtica dioica. For health care providers. (Source: NCCAM Featured Content)
Source: NCCAM Featured Content - June 16, 2016 Category: Complementary Medicine Authors: NCCIH Source Type: news

Boston Scientific wins UK NICE support for GreenLight laser therapy
Boston Scientific (NYSE:BSX) said Tuesday that the U.K.’s National Institute for Health and Care Excellence now provides guidance supporting the use of its GreenLight XPS laser therapy system used to treat prostatic enlargement in patients with benign prostatic hyperplasia. NICE, which provides evidence-based guidance and standards to the U.K.’s National Health Service, said that adoption of the GreenLight XPS system to treat non high-risk patients with BPH can “significantly reduce costs for the NHS,” Marlborough, Mass.-based Boston Scientific said. “The GreenLight XPS System is a well-e...
Source: Mass Device - June 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Urology Boston Scientific Source Type: news